Last reviewed · How we verify

NCT05194696

Caffeine Consumption and Cataract Prevention

Status unknown Last updated 31 January 2022
What this trial tests

trial testing Questionnaire in Cataract in 12,000 participants. Status unknown.

Timeline
1 September 2020
Primary endpoint
1 September 2024
1 September 2025

Quick facts

Lead sponsorVienna Institute for Research in Ocular Surgery
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment12,000
Start date1 September 2020
Primary completion1 September 2024
Estimated completion1 September 2025
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Vienna Institute for Research in Ocular Surgery

Who can join

Adults 21 to 105, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effect of peroral caffeine consumption on the delay of cataract onset.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Human retinal secretome: A cross-link between mesenchymal and retinal cells.
    Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Vienna Institute for Research in Ocular Surgery trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05194696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing